| Literature DB >> 30621739 |
Liza Selley1, David H Phillips2,3, Ian Mudway2,3.
Abstract
BACKGROUND: Combustion of biodiesels in place of fossil diesel (FD) has been proposed as a method of reducing transport-related toxic emissions in Europe. While biodiesel exhaust (BDE) contains fewer hydrocarbons, total particulates and carbon monoxide than FD exhaust (FDE), its high nitrogen oxide and ultrafine particle content may still promote pulmonary pathophysiologies. MAIN BODY: Using a complement of in vitro and in vivo studies, this review documents progress in our understanding of pulmonary responses to BDE exposure. Focusing initially on hypothesis-driven, targeted analyses, the merits and limitations of comparing BDE-induced responses to those caused by FDE exposure are discussed within the contexts of policy making and exploration of toxicity mechanisms. The introduction and progression of omics-led workflows are also discussed, summarising the novel insights into mechanisms of BDE-induced toxicity that they have uncovered. Finally, options for the expansion of BDE-related omics screens are explored, focusing on the mechanistic relevance of metabolomic profiling and offering rationale for expansion beyond classical models of pulmonary exposure.Entities:
Keywords: Biodiesel; Hypothesis generation; Mechanism; Metabolomics; Pulmonary toxicity; Transcriptomics
Mesh:
Substances:
Year: 2019 PMID: 30621739 PMCID: PMC6504167 DOI: 10.1186/s12989-018-0284-y
Source DB: PubMed Journal: Part Fibre Toxicol ISSN: 1743-8977 Impact factor: 9.400
Fig. 1Major techniques and technologies employed during molecular profiling. Typical numbers of molecules detectable by each platform (during a full platform analysis) are displayed in brackets
Documented cytokine secretion profiles for pulmonary cells or tissues following exposure to biodiesel emissions
| Study | Malorni et al. 2017 [ | Fukagawa et al. 2013 [ | Yanamala et al. 2013 [ | Shvedova et al. 2013 [ | ||||
|---|---|---|---|---|---|---|---|---|
| Exposure | 20% FAME PM0.1 (organic fraction) | 20% SME | 100% FAME | 100% SME | ||||
| Model | A549 | THP-1 | BEAS-2B | Mouse lung | Mouse BALF | Mouse lung | Mouse BALF | Mouse Lung |
| bFGF |
|
|
|
|
|
|
|
|
| CCL5 (RANTES) |
|
|
|
|
|
|
|
|
| CXCL1 (KC) |
|
|
|
|
|
|
|
|
| CXCL9 (MIG) |
|
|
|
|
|
|
|
|
| Eotaxin |
|
|
|
|
|
|
|
|
| G-CSF |
|
|
|
|
|
|
|
|
| GM-CSF |
|
|
|
|
|
|
|
|
| IL-10 |
|
|
|
|
|
|
|
|
| IL-12p40 |
|
|
|
|
|
|
|
|
| IL-12p70 |
|
|
|
|
|
|
|
|
| IL-13 |
|
|
|
|
|
|
|
|
| IL-15 |
|
|
|
|
|
|
|
|
| IL-17 |
|
|
|
|
|
|
|
|
| IL-18 |
|
|
|
|
|
|
|
|
| IL-1α |
|
|
|
|
|
|
|
|
| IL-1β |
|
|
|
|
|
|
|
|
| IL-1ra |
|
|
|
|
|
|
|
|
| IL-2 |
|
|
|
|
|
|
|
|
| IL-3 |
|
|
|
|
|
|
|
|
| IL-4 |
|
|
|
|
|
|
|
|
| IL-5 |
|
|
|
|
|
|
|
|
| IL-6 |
|
|
|
|
|
|
|
|
| IL-7 |
|
|
|
|
|
|
|
|
| IL-8 |
|
|
|
|
|
|
|
|
| IL-9 |
|
|
|
|
|
|
|
|
| IFNγ |
|
|
|
|
|
|
|
|
| IP-10 |
|
|
|
|
|
|
|
|
| LIF |
|
|
|
|
|
|
|
|
| MCP-1 |
|
|
|
|
|
|
|
|
| M-CSF |
|
|
|
|
|
|
|
|
| MIP-1α |
|
|
|
|
|
|
|
|
| MIP-1β |
|
|
|
|
|
|
|
|
| MIP-2 |
|
|
|
|
|
|
|
|
| PDGF |
|
|
|
|
|
|
|
|
| TNF-α |
|
|
|
|
|
|
|
|
| VEGF |
|
|
|
|
|
|
|
|
↑ represents statistically significant increase in secretion compared with particle-free controls while ↓ represents statistically significant decreases in secretions. – demonstrates no statistically significant change in secretion compared with non-exposed controls and N indicates instances where a cytokine species was not measured. Basic Fibroblast growth factor (bFGF), Chemokine (C-C-motif) ligand (CCL), Chemokine (C-X-C motif) ligand (CXCL), Granulocyte-colony stimulating factor (G-CSF), Interferon-γ neutralising (IFNγ), Interferon-γ-induced protein 10 (IP-10), Leukaemia inhibitory factor (LIF), Monocyte chemoattractant protein-1 (MCP-1), Macrophage colony stimulating factor (M-CSF), Macrophage inflammatory protein (MIP), Platelet-derived growth factor (PDGF), Tumour necrosis factor-α (TNF-α), Vascular endothelial growth factor (VEGF)
Fig. 2General overview of known molecular and cellular features of pulmonary responses to BDE exposure, including details detected via targeted (a) and untargeted (b) experimental approaches in samples harvested from human cohorts or in vitro and in vivo models of human and rodent airways